Evaluation of oxidative stress and inflammatory biomarkers in diabetic patients treated with metformin and empagliflozin: a cross-sectional study
Abstract
Type 2 diabetes mellitus (T2DM) is associated with persistent oxidative stress and chronic low-grade inflammation, which accelerate vascular and metabolic complications. Metformin and empagliflozin are widely prescribed oral antidiabetic agents, each with potential pleiotropic benefits beyond glucose lowering. Comparative data on their effects on oxidative and inflammatory biomarkers in South Asian populations remain limited. Objective: To evaluate oxidative stress and inflammatory biomarkers in T2DM patients treated with metformin and empagliflozin compared with healthy controls. Methods: This cross-sectional study was carried out between January 2024 and January 2025 at the Sughra Shafi Medical Complex in Narowal and the Ittefaq Hospital Trust in Lahore. A total of 150 people were enrolled: 50 T2DM patients using metformin, 50 taking empagliflozin, and 50 healthy controls of similar age and gender. Demographic and clinical information was collected. Fasting glucose, HbA1c, and lipid profile were all investigated in the laboratory. Oxidative stress indicators (MDA, SOD, catalase) and inflammatory biomarkers (IL-6, hs-CRP) were also assessed. The data was analyzed using SPSS v26 with one-way ANOVA, and p < 0.05 was considered statistically significant. Results: Diabetic patients exhibited significantly higher MDA, hs-CRP, and IL-6 levels compared with controls (p < 0.001). Empagliflozin-treated patients had significantly lower MDA (3.3 ± 0.5 µmol/L) and IL-6 (5.0 ± 1.3…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 150 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.